FDA approves first maternal RSV vaccine to protect newborns through first months of life

The FDA approved Pfizer's maternal RSV vaccine Abrysvo, given during pregnancy to pass antibodies to infants.
Abrysvo was 82% effective against severe RSV disease in infants' first 3 months and 69% in first 6 months.
RSV is a common respiratory infection that can cause severe illness in infants and older adults.
An RSV antibody injection for infants and a vaccine for older adults were also recently approved.
The vaccine still needs CDC recommendation before being made available to pregnant women.